KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Operating Expenses (2016 - 2025)

Abbott Laboratories' Operating Expenses history spans 17 years, with the latest figure at $9.2 billion for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.6% year-over-year to $9.2 billion; the TTM value through Dec 2025 reached $36.3 billion, up 3.27%, while the annual FY2025 figure was $36.3 billion, 3.27% up from the prior year.
  • Operating Expenses for Q4 2025 was $9.2 billion at Abbott Laboratories, down from $9.3 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $9.3 billion in Q3 2025 and bottomed at $8.2 billion in Q1 2023.
  • The 5-year median for Operating Expenses is $8.7 billion (2024), against an average of $8.7 billion.
  • The largest annual shift saw Operating Expenses skyrocketed 32.68% in 2021 before it dropped 8.29% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $9.1 billion in 2021, then decreased by 3.33% to $8.8 billion in 2022, then dropped by 3.71% to $8.5 billion in 2023, then increased by 7.11% to $9.1 billion in 2024, then grew by 1.6% to $9.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Operating Expenses are $9.2 billion (Q4 2025), $9.3 billion (Q3 2025), and $9.1 billion (Q2 2025).